Form 4: Deep Track Capital Sells 56,000 Shares of Nektar Therapeutics

Deep Track Capital, a significant shareholder in Nektar Therapeutics, recently sold 56,000 shares of common stock at an average price of $1.7791.

Summary

• On May 10, 2024, Deep Track Capital, LP sold 56,000 shares of Nektar Therapeutics (NKTR) common stock.
• The shares were sold at a weighted average price of $1.7791, with individual transactions ranging from $1.745 to $1.81.
• Following the transaction, Deep Track Capital, through its affiliated fund Deep Track Biotechnology Master Fund, Ltd., still beneficially owns 18,344,000 shares of Nektar Therapeutics.
• David Kroin, as the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, may be deemed the beneficial owner of these shares.
• Deep Track Capital, L.P. and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The sale of shares could be interpreted negatively, but without further context, it's a routine disclosure.

Negatives

• Deep Track Capital reduced its holdings in Nektar Therapeutics by selling 56,000 shares.

Management Comments

• Deep Track Capital, L.P. and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell the company's stock; this provides transparency to the market.

Comparison to Industry Standards

• Form 4 filings are a standard part of regulatory compliance for publicly traded companies and their significant shareholders.
• Similar filings are made by insiders of companies like Amgen, Biogen, and Gilead Sciences when they trade their company's stock.

Stakeholder Impact

• The sale of shares by a significant shareholder like Deep Track Capital could potentially influence investor sentiment regarding Nektar Therapeutics.
• The impact on other stakeholders is likely minimal unless this transaction signals a larger strategic shift.

Key Dates